Mesothelioma

New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma

2024-06-22

  • Study



  • Efficacy



  • Safety




    • J Clin Oncol 2023 41:17_suppl, LBA8505

    Chu QS IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

    http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA8505

    Reviewed by Ulas D. Bayraktar, MD on Jun 22, 2024